吡柔比星联合维拉帕米膀胱灌注对膀胱癌术后复发的预防效果分析

目的:探讨吡柔比星联合维拉帕米膀胱灌注治疗应用于膀胱上皮癌术后复发的效果及安全性。方法:将本院收治的54例膀胱上皮癌行经尿道膀胱肿瘤电切术(TURBT)或膀胱部分切除术患者随机分为实验组和对照组,实验组患者给予吡柔比星联合维拉帕米膀胱灌注治疗,对照组患者给予吡柔比星膀胱灌注治疗。随访观察5年,比较两组患者1年、3年、5年的累计复发率,以及治疗过程中膀胱刺激征、血尿、化学性膀胱炎等不良反应发生率。结果:实验组1年、3年、5年的累计复发率分别为3.7%、7.4%、11.1%,不良反应发生率为51.9%;对照组1年、3年、5年的累计复发率分别为14.8%、29.6%、37.0%,不良反应发生率为48.1%。实验组3年、5年累积复发率显著低于对照组(P<0.05),不良反应发生率无显著差异(P>0.05)。结论:在吡柔比星膀胱灌注的基础上,联合应用维拉帕米能够显著降低膀胱上皮癌术后复发率并保留患者的性功能,且安全性较高,值得临床推广应用。

Intravesical instillation with combined use of THP and verapamil in preventing the recurrence of bladder cancer

Objectives： To explore the effect of intravesical instillation with combined use of pirarubicin and verapamil on preventing the recurrence of bladder cancer. Methods： Fifty - four patients with urothelial carcinoma treated with transarethral resection of bladder tumor （TURBT） or partial cystectomy in our hospital were randomly divided into the experimental group and the control group. The experimental group was treated with THP combined with verapamil, while the control group were treated with only THP. 1 -year, 3 -year, 5 -year cumulative recurrence rates of two groups were analyzed as well as adverse reactions such as hematuria, chemical cystitis. Results ： 1 - year, 3 - year, 5 - year cumulative recurrence rates of the experimental group were 3.7% , 7.4% , 11.1% , and the incidence of adverse reactions was 51.9% ; 1 - year, 3 - year, 5 - year cumulative recur- rence rates of the control group were 14. 8% , 29. 6% , 37.0% , and the incidence of adverse reactions was 48. 1%. 3 - year, 5 - year cumulative recurrence rates of the experimental group were significantly lower than those of the control group （ P 〈 0. 05 ）, and there was no significant difference in the incidence of adverse reactions （P 〉0. 05）. Conclusion： THP joint with verapamil is significantly better than THP in terms of preventing recurrence of bladder cancer and preserving sexual ability. It is of relatively high safety and worthy of clinical application.